Invention Grant
US07790870B1 Membrane-anchored GP41 peptides that inhibit subsequent HIV viral entry
有权
膜锚定的GP41肽，其抑制随后的HIV病毒进入
- Patent Title: Membrane-anchored GP41 peptides that inhibit subsequent HIV viral entry
- Patent Title (中): 膜锚定的GP41肽，其抑制随后的HIV病毒进入
-
Application No.: US10148064Application Date: 2000-11-24
-
Publication No.: US07790870B1Publication Date: 2010-09-07
- Inventor: Meike-Dorothee von Laer
- Applicant: Meike-Dorothee von Laer
- Applicant Address: DE Hamburg
- Assignee: Heinrich-Pette-Institut
- Current Assignee: Heinrich-Pette-Institut
- Current Assignee Address: DE Hamburg
- Agency: Arnold & Porter LLP
- Priority: DE19957838 19991125
- International Application: PCT/EP00/11733 WO 20001124
- International Announcement: WO01/37881 WO 20010531
- Main IPC: C07H21/04
- IPC: C07H21/04 ; A01N43/04 ; A61K31/70 ; C12N15/00 ; C07K14/00 ; C07K17/00
Abstract:
The invention relates to the genetically engineered treatment of an HIV infection by the expression of membrane-anchored gp41 peptides. With this treatment vectors are made available for the first time which code for a fusion protein that contains a peptide derived from gp41 of HIV and a carboxy terminal by means of a trans-membrane anchor tagged to a flexible linker.
Information query
